期刊文献+

阿米洛利抑制尿激酶受体表达及减少蛋白尿的机制 被引量:1

Amiloride reduces proteinuria and inhibits podocyte uPAR in the 5/6 nephrectomy rats
下载PDF
导出
摘要 目的观察阿米洛利在经典的5/6肾切除大鼠模型中对蛋白尿的影响,探讨其影响蛋白尿的机制。方法构建经典的5/6肾切除大鼠模型,实验分为3组:假手术对照组(Sham)、5/6肾切除组(NTX)、5/6肾切除+阿米洛利干预组(NTX+阿米洛利)。采用考马斯亮蓝法检测各组24 h尿蛋白,利用免疫荧光共聚焦、实时荧光定量PCR等技术,检测足细胞尿激酶受体(uPAR)蛋白和uPAR mRNA的表达情况。结果第2周时,与假手术对照组(Sham)相比较,5/6肾切除组(NTX)24 h尿蛋白明显升高(47.50±28.05 mg vs 14.28±3.8 mg,P=0.023),有统计学意义;与NTX组相比,NTX+阿米洛利24 h尿蛋白无统计学意义(51.56±21.03 mg vs 47.50±28.05 mg,P=0.748)。第12周时,与NTX组(188.31±29.82)mg相比,NTX+阿米洛利组(121.37±31.14)mg、Sham组(21.32±8.59)mg 24 h尿蛋白增加量均进一步减少,具有统计学意义[P值分别为0.001,0.000]。激光共聚焦显微镜观察,与Sham组相比较,NTX组PLAUR mRNA表达明显增高(9.74±1.44 vs 1.01±0.13,P<0.01),有统计学意义;与NTX组相比较,NTX+阿米洛利mRNA表达明显降低(9.74±1.44 vs 5.01±1.36,P<0.01),有统计学意义。结论阿米洛利可能通过抑制受损足细胞uPAR的表达,从而起到降蛋白尿、延缓肾小球硬化的作用。 Objective To observe the effect of amiloride on the proteinuria of the 5/6 nephrectomy rats. Methods To establish the 5/6 nephrectomy rats model and divide the experiment into 3 groups, sham operated group(Sham), 5/6 nephrectomy model group(NTX) and 5/6 nephrectomy with amiloride-treated group (NTX+amiloride, n=15). The concentration of protein and mRNA of uPAR and the change of podocytes motility were detected by coomassiebluestaining, immunofluorence method and real-time PCR. Results At second week, compared with Control group, the 24 h urine protein of NTX group was significantly increased (47.50±28.05 mg vs 14.28±3.8 mg, P=0.023). There was no statistical significance in 24-hour urine protein between NTX+amiloride group and NTX group (51.56±21.03 mg vs 47.50±28.05 mg, P=0.748). The same situation was also observed at the time point of 12 week, comparing with NTX group, 24-hour urine protein decreased in Sham group (188.31±29.82 mg vs 21.32±8.59 mg, P=0.000) and NTX+amiloride group (188.31±29.82 mg vs 121.37±31.14 mg, P=0.000), with statistical significance when comparing with Sham group, the expression of uPAR mRNA in NTX group was significantly increased (9.74±1.44 vs 1.01±0.13, P=0.000). In contrast, the expression of uPAR mRNA in NTX rats treated with amiloride was significantly lower than in NTX group (9.74±1.44 vs 5.01±1.36, P=0.000). Conclusion Amiloride can reduce the proteinuria of the 5/6 nephrectomy rats model of transient proteinuria by inhibiting the induction of uPAR expression.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2014年第11期1654-1657,共4页 Journal of Southern Medical University
基金 国家自然科学基金(81370808)~~
关键词 尿激酶受体 阿米洛利 足细胞 蛋白尿 urokinase receptor, amiloride podocyte proteinuria
  • 相关文献

参考文献16

  • 1Zandi-Nejad K, Eddy AA, Glassock RJ, et al. Why is proteinuria an ominous biomarker of progressive kidney disease [J]. Kidney Int Suppl, 2004, 66(92): $76-89.
  • 2Yuan H, Takeuchi E, Salant DJ. Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton[J]. Am J Physiol Renal Physiol, 2002, 282(4): F585-91.
  • 3A1 Mana H, Akhtar M. Molecular basis of proteinuria[J]. Adv Anat Pathol, 2003, 23(5): 244-8.
  • 4Jefferson JA, Shankland S J, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint [J]. Kidney Int, 2008, 74 (1): 22-36.
  • 5Akhtar M. Molecular basis of proteinuria[J]. Adv Anat Pathol, 2004, 11(6): 304-9.
  • 6Wei CL, Moeller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor[J]. Nat Med, 2008, 14 (1): 55-63.
  • 7Pearce D. The role of SGK1 in hormone-regulated Sodium transport [J]. Trends Endocrinol Metab, 2001, 12(8): 341-7.
  • 8Wang Y, Jones C J, Dang J, et al. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells[J]. FEBS Lett, 1994, 353: 138-42.
  • 9Wu SS, Murrell GA, Wang Y. Interferon-alpha (Intron A).upregulates urokinase-type plasminogen activator receptor gene expression[J]. Cancer Immunol Immunother, 2002, 51 (5): 248-54.
  • 10Keane WF. Proteinuria: its clinical importance and role in progressive renal disease[J]. Am J Kidney Dis, 2000, 35(4 Suppll ): s97-105.

二级参考文献10

  • 1ASANUMA K, MUNDEL P. The role of podocytes in glomerular pathobiology [J]. Clin Exp Nephrol, 2003,7(4) :255-259.
  • 2BLASI .F, CARMELIET P. uPAR: a versatile signaling orchestrator [J]. Nat Rev Mol Cell Biol, 2002, 3 (12) : 932-943.
  • 3WEI C, MOLLER CC, ALTINTAS MM, et al. Modification of kidney barrier function by the urokinase receptor [J]. Nat Med, 2008, 14(1 ) :55-63.
  • 4WANG Y, JONES C J, DANG J, et al. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells [J]. FEBS Lett, 1994, 353(2): 138-142.
  • 5WU S, MURRELL GA, WANG Y. Interferon-alpha (Intron A) upregulatcs urokinase-type plasminogen activator receptor gene expression [J]. Cancer Immunol Immunother, 2002, 51 (5) : 248- 254.
  • 6SHANKLAND SJ, PIPPIN JW, REISER J, et al. Podocyte in culture : past, present, and future [J]. Kidney Int, 2007, 72 ( 1 ) : 26-36.
  • 7ASANUMA K, YANAGIDA-ASANUMA E, FAUL C, et al. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling [J]. Nat Cell Biol, 2006, 8 (5): 485 -491.
  • 8ZANDI-NEJAD K, EDDY AA, GLASSOCK RJ, et al. Why is proteinuria an ominous biomarker of progressive kidney disease? [J]. Kidney Int Suppl, 2004, (92) : S76-S89.
  • 9PATRAKKA J, TRYGGVASON K. New insights into the role of podocytes in proteinuria [J]. Nat Rev Nephrol, 2009, 5(8) : 463- 468.
  • 10杨芸,史伟,章斌,李东风.环孢素对脂多糖诱导足细胞活动力改变的影响[J].中国新药与临床杂志,2009,28(11):814-818. 被引量:3

共引文献2

同被引文献14

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部